Company Profile

Immunotope Inc (AKA: Immunotope Diagnostics Inc)
Profile last edited on: 9/20/17      CAGE: 393K4      UEI:

Business Identifier: Immunotherapeutics for treatment and prevention of cancer and chronic viral infections
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3805 Old Easton Road
Doylestown, PA 18901
   (215) 253-4180
Location: Multiple
Congr. District: 01
County: Bucks

Public Profile

In January 2008 ImmunoVaccine Technologies Inc agreed to acquire Immunotope Inc. with the small firm operating as a subsidiary of ImmunoVaccine Technologies, Inc. Immunotope, Inc., a clinical stage biotechnology company, develops immunotherapy products for the treatment and prevention of cancer and chronic viral infections. The company focuses on the unmet need to diagnose cancer at its earliest stages and to provide effective treatments that destroy tumors and prevent recurrence and metastasis. Its products include IMT-1012, an OCPM immunotherapeutic vaccine and a multivalent cancer therapeutic mixture of various novel antigens that targets a pathway present in tumors for the treatment of ovarian, colon, and breast cancer; and an investigational new drug application for ovarian cancer patients. The company’s clinical and preclinical programs consist of a cancer immunotherapy program to elicit immunity in the patient to destroy tumor cells; pre clinical and cancer diagnostics programs; and an infectious disease program that focuses on immunotherapeutics for chronic viral diseases, including hepatitis B/C and HIV. In addition, it offers various novel antigens, including ovarian tumor antigens, breast tumor antigens, antibody therapeutic targets, cancer diagnostic targets, and ovarian and prostate theranostic targets for clinical evaluation and out licensing. Further, the company provides immunoproteomics services for antigen discovery and characterization, which include the analysis of MHC processing of proteins in genetic constructs and the analysis of antigen specificity post cell-based immunotherapies. It uses immunoproteomics technologies to identify naturally processed and presented antigens associated with histocompatibility complex class I and class II molecules present on diseased cell

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Ramila Philip -- President and Chief Operating Officer

  Lorraine Keller -- Vice President Corporate Development

  Anand D Mehta

  Mohan Philip

  Paul von Hoegen -- Vice President Business Development and Managing Director